Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Table 3

Overall survival.

Experimental treatments	Control treatment	HR	95% CI	𝑃 value
Cabazitaxel	Mitoxantrone	0.81	0.48–1.37	0.43
Abiraterone and enzalutamide	Placebo	0.72	0.52–0.99	0.046
All treatments in PS 2 patients		0.74	0.56–0.98	0.035